ES2164465T3 - Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. - Google Patents

Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.

Info

Publication number
ES2164465T3
ES2164465T3 ES98961174T ES98961174T ES2164465T3 ES 2164465 T3 ES2164465 T3 ES 2164465T3 ES 98961174 T ES98961174 T ES 98961174T ES 98961174 T ES98961174 T ES 98961174T ES 2164465 T3 ES2164465 T3 ES 2164465T3
Authority
ES
Spain
Prior art keywords
neuronal
aminometil
chromans
replaced
avoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98961174T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Fahrig
Irene Gerlach
Ervin Horvath
Reinhard Jork
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2164465T3 publication Critical patent/ES2164465T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES98961174T 1997-11-24 1998-11-11 Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal. Expired - Lifetime ES2164465T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Publications (1)

Publication Number Publication Date
ES2164465T3 true ES2164465T3 (es) 2002-02-16

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98961174T Expired - Lifetime ES2164465T3 (es) 1997-11-24 1998-11-11 Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.

Country Status (30)

Country Link
US (2) US6235774B1 (https=)
EP (1) EP1051170B1 (https=)
JP (1) JP2001523716A (https=)
KR (1) KR20010032357A (https=)
CN (1) CN1134256C (https=)
AR (1) AR016973A1 (https=)
AT (1) ATE206615T1 (https=)
AU (1) AU745759B2 (https=)
BG (1) BG64167B1 (https=)
CA (1) CA2311126A1 (https=)
DE (2) DE19751949A1 (https=)
DK (1) DK1051170T3 (https=)
ES (1) ES2164465T3 (https=)
HN (1) HN1998000169A (https=)
HU (1) HUP0004369A3 (https=)
IL (1) IL135904A (https=)
IS (1) IS5496A (https=)
MY (1) MY118414A (https=)
NO (1) NO20002638L (https=)
NZ (1) NZ504656A (https=)
PE (1) PE134999A1 (https=)
PL (1) PL340674A1 (https=)
PT (1) PT1051170E (https=)
RU (1) RU2217140C2 (https=)
SI (1) SI1051170T1 (https=)
SV (1) SV1998000138A (https=)
TR (1) TR200001471T2 (https=)
TW (1) TW524690B (https=)
WO (1) WO1999026621A1 (https=)
ZA (1) ZA9810668B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
BR0109193A (pt) * 2000-03-17 2003-05-27 Alcon Inc Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
AU2002355170B2 (en) * 2001-07-26 2007-06-07 Merck Patent Gmbh Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
BR0212199A (pt) * 2001-09-12 2004-10-05 Merck Patent Gmbh Uso de aminometil cromanos substituìdos no tratamento de distúrbios do movimento
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE19522088A1 (de) 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
ZA9810668B (en) 1999-05-26
NO20002638D0 (no) 2000-05-23
WO1999026621A1 (de) 1999-06-03
BG104466A (en) 2001-02-28
HUP0004369A2 (hu) 2001-04-28
US20010018530A1 (en) 2001-08-30
SI1051170T1 (en) 2001-12-31
PE134999A1 (es) 2000-03-05
DK1051170T3 (da) 2001-12-27
MY118414A (en) 2004-10-30
PL340674A1 (en) 2001-02-12
AR016973A1 (es) 2001-08-01
BG64167B1 (bg) 2004-03-31
RU2217140C2 (ru) 2003-11-27
CN1279604A (zh) 2001-01-10
EP1051170A1 (de) 2000-11-15
EP1051170B1 (de) 2001-10-10
HN1998000169A (es) 1999-11-03
NZ504656A (en) 2002-02-01
TR200001471T2 (tr) 2000-10-23
AU745759B2 (en) 2002-03-28
US6235774B1 (en) 2001-05-22
ATE206615T1 (de) 2001-10-15
KR20010032357A (ko) 2001-04-16
IL135904A0 (en) 2001-05-20
TW524690B (en) 2003-03-21
JP2001523716A (ja) 2001-11-27
US6331561B2 (en) 2001-12-18
HUP0004369A3 (en) 2002-04-29
SV1998000138A (es) 1999-05-25
DE19751949A1 (de) 1999-05-27
AU1668599A (en) 1999-06-15
IS5496A (is) 2000-05-15
PT1051170E (pt) 2002-02-28
CN1134256C (zh) 2004-01-14
CA2311126A1 (en) 1999-06-03
IL135904A (en) 2003-07-06
NO20002638L (no) 2000-05-23
DE59801724D1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
ES2164465T3 (es) Uso de aminometil-cromanos sustituidos para evitar la degeneracion neuronal y para estimular la regeneracion neuronal.
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2161290T3 (es) Derivados de quinazolina.
ES2182161T3 (es) Utilizacion de derivados de pirimidina para la preparacion de un medicamento para la prevencion del cancer.
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
ES2166379T3 (es) 2-aminotetralinas sustituidas.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
ECSP024399A (es) Derivados de benzotiazol
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
ES2179945T3 (es) Compuestos de tetralina con actividad de resistencia a multiples farmacos.
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
AR018505A1 (es) COMPOSICIoN FARMACÉUTICA ANTIHISTAMíNICA CON UN INHIBIDOR DE LA P-GLICOPROTEíNA Y EL USO DE DICHA COMPOSICIoN PARA LA FABRICACIoN DE MEDICAMENTOS PARA AUMENTAR LA BIODISPONIBILIDAD DE DICHO ANTIHISTAMíNICO.
ES2105285T3 (es) Nuevos derivados de la adenosina, sus procedimientos de preparacion, composiciones farmaceuticas que los contienen.
ES2066914T3 (es) Factores a1, a2, a3 y h del antibiotico ge 2270.
ES2161953T3 (es) Utilizacion del monosialogangliosido gm1 o del n-dicloroacetil-liso-gm1 para prevenir o invertir la degeneracion neuronal inducida por un tratamiento de larga duracion con l-dopa en la terapia de la enfermedad de parkinson.
PE20011260A1 (es) Derivados de sulfonamida

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1051170

Country of ref document: ES